Alnylam Pharmaceuticals Inc (ALNY):企業の財務・戦略的SWOT分析

◆英語タイトル:Alnylam Pharmaceuticals Inc (ALNY) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH66532FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥32,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥48,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Alnylam Pharmaceuticals Inc (ALNY) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company, which discovers, develops and commercializes therapeutics based on RNAi interference. The company’s marketed RNAi therapeutics include, Onpattro, is used in treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis; Givlaari for treatment of acute hepatic porphyria, Oxlumo developed for treatment of primary hyperoxaluria type 1 (PH1). The company develops a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic infectious diseases, cardio-metabolic diseases, and central nervous system (CNS) diseases. Its late-stage product candidates include vutrisiran for ATTR amyloidosis, inclisiran for hypercholesterolemia, fitusiran for hemophilia and rare bleeding disorders, and lumasiran for severe PH1. The company operates subsidiaries in the US, Austria, Belgium, Bermuda, Canada, France, Germany, Italy, Japan, Taiwan, Portugal, Spain, Sweden, the Netherlands, Switzerland, Czech Republic, and the UK. Alnylam is headquartered in Cambridge, Massachusetts, the US.

Alnylam Pharmaceuticals Inc Key Recent Developments

Apr 15,2021: Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results
Apr 06,2021: Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference
Mar 11,2021: Alnylam issues inaugural corporate responsibility summary
Feb 18,2021: Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
Feb 11,2021: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Alnylam Pharmaceuticals Inc – Key Facts
Alnylam Pharmaceuticals Inc – Key Employees
Alnylam Pharmaceuticals Inc – Key Employee Biographies
Alnylam Pharmaceuticals Inc – Major Products and Services
Alnylam Pharmaceuticals Inc – History
Alnylam Pharmaceuticals Inc – Company Statement
Alnylam Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Alnylam Pharmaceuticals Inc – Business Description
Product Category: Product Revenue
Performance
Product Category: Revenue from Collaborations
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: The US
Performance
R&D Overview
Alnylam Pharmaceuticals Inc – Corporate Strategy
Alnylam Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Alnylam Pharmaceuticals Inc – Strengths
Alnylam Pharmaceuticals Inc – Weaknesses
Alnylam Pharmaceuticals Inc – Opportunities
Alnylam Pharmaceuticals Inc – Threats
Alnylam Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alnylam Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 15, 2021: Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results
Apr 06, 2021: Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference
Mar 11, 2021: Alnylam issues inaugural corporate responsibility summary
Feb 18, 2021: Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
Feb 11, 2021: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
Jan 10, 2021: Alnylam launches “Alnylam P⁵x25” strategy for planned transition to a top five biotech in market capitalization over next five years
Dec 21, 2020: Alnylam appoints Tolga Tanguler chief commercial officer and also announces new CEMEA, medical affairs, and compliance leaders
Dec 15, 2020: Alnylam announces 2021 product and pipeline goals and provides program updates at R&D Day
Dec 08, 2020: CENTOGENE and Alnylam Pharmaceuticals launch a new clinical program aimed at revolutionizing the diagnosis of hereditary transthyretin-related amyloidosis (“ATTRv”)
Dec 07, 2020: Alnylam issues 2nd Annual Patient Access Philosophy report highlighting broad access to the company’s approved therapies
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Alnylam Pharmaceuticals Inc, Key Facts
Alnylam Pharmaceuticals Inc, Key Employees
Alnylam Pharmaceuticals Inc, Key Employee Biographies
Alnylam Pharmaceuticals Inc, Major Products and Services
Alnylam Pharmaceuticals Inc, History
Alnylam Pharmaceuticals Inc, Subsidiaries
Alnylam Pharmaceuticals Inc, Joint Venture
Alnylam Pharmaceuticals Inc, Key Competitors
Alnylam Pharmaceuticals Inc, Ratios based on current share price
Alnylam Pharmaceuticals Inc, Annual Ratios
Alnylam Pharmaceuticals Inc, Annual Ratios (Cont...1)
Alnylam Pharmaceuticals Inc, Interim Ratios
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alnylam Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alnylam Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Alnylam Pharmaceuticals Inc (ALNY):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Ann Inc:企業の戦略的SWOT分析
    Ann Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Fukoku Mutual Life Insurance Company:企業の戦略・SWOT・財務分析
    Fukoku Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Fukoku Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Altacor Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Altacor Ltd (Altacor) is an ophthalmology company that develops and markets products for chronic eye conditions. The company offers prescription and retail ophthalmology products. Its products comprise liquid gel, eye drop, eye mask, eyelid cleaner, nutritional supplement, and others. Altaco …
  • Sarossa plc-製薬・医療分野:企業M&A・提携分析
    Summary Sarossa plc (Sarossa), formerly Sarossa Capital Limited, is an investment holding and management company. The company principally makes investment in and growth and development of businesses which present opportunities for value creation. It focuses on portfolio investment in major internati …
  • Investor AB (INVE B):企業の財務・戦略的SWOT分析
    Investor AB (INVE B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Global Clean Energy Holdings Inc:企業の戦略的SWOT分析
    Global Clean Energy Holdings Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • IAC/INTERACTIVECORP:企業の戦略・SWOT・財務分析
    IAC/INTERACTIVECORP - Strategy, SWOT and Corporate Finance Report Summary IAC/INTERACTIVECORP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Whole Foods Market Inc:企業の戦略・SWOT・財務情報
    Whole Foods Market Inc - Strategy, SWOT and Corporate Finance Report Summary Whole Foods Market Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Citizens Electric Corporation:企業の発電所・SWOT分析2018
    Citizens Electric Corporation - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Tethys Oil AB (TETY):企業の財務・戦略的SWOT分析
    Summary Tethys Oil AB (Tethys Oil) is an upstream oil and gas company that offers exploration, development and production of oil and natural gas reserves. The company holds onshore exploration licences in Lithuania and France. Tethys Oil holds Gargzdai license, Rietavas license and Raseiniai license …
  • Calibre Group Ltd:企業の戦略・SWOT・財務情報
    Calibre Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Calibre Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Suedzucker Ag:企業の戦略・SWOT・財務分析
    Suedzucker Ag - Strategy, SWOT and Corporate Finance Report Summary Suedzucker Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Michael Kors Holdings Ltd:企業の戦略・SWOT・財務情報
    Michael Kors Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Michael Kors Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Biosense Webster Inc:医療機器:M&Aディール及び事業提携情報
    Summary Biosense Webster Inc (Biosense Webster), a subsidiary of Johnson & Johnson, is a medical device company that designs, manufactures and markets cardiac arrhythmias products. The company’s products include ablation catheters, diagnostic catheters and access, ultrasound catheters and 3D cardiac …
  • Pfizer Inc (PFE)-医療機器分野:企業M&A・提携分析
    Summary Pfizer Inc (Pfizer) is a biopharmaceutical company, which discovers, develops, manufactures and markets healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products to treat various conditions including infection, cancer, inflammation, …
  • Acorn Energy Inc (ACFN):企業の財務・戦略的SWOT分析
    Acorn Energy Inc (ACFN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Pathfinder Energy Pty Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Pathfinder Energy Pty Ltd (Pathfinder) is an oil and gas company that offers exploration and development of conventional and unconventional oil and gas resources. The company acquires exploration permits and matures prospects using geophysics and geology. It maintains exploration licenses in …
  • Baidu, Inc.:企業の戦略・SWOT・財務情報
    Baidu, Inc. - Strategy, SWOT and Corporate Finance Report Summary Baidu, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • CMC Biologics AS:製薬・医療:M&Aディール及び事業提携情報
    Summary CMC Biologics A/S (CMC Biologics), formerly CMC Biopharmaceuticals A/S, a subsidiary of Asahi Glass Co., Ltd., is a contract process development and manufacturer of biopharmaceuticals. The company's service portfolio encompasses process development, cGMP manufacturing, and quality and regula …
  • Nordic Nanovector ASA (NANO):企業の財務・戦略的SWOT分析
    Summary Nordic Nanovector ASA (Nordic Nanovector), formerly Nordic Nanovector AS is a developer and commercializer of antibody radionuclide conjugates for the treatment of hematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed for …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆